

ESMO Advanced Course on Immunotherapy in Lung Cancer : a new Paradigm with unanswered Questions

Programme

ZURICH
SWITZERLAND

3-4 JULY 2019

Co-Chairs

John B.A.G. Haanen, NL
Aurélien Marabelle, FR

ESMO ADVANCED COURSE ON LUNG CANCER IN IMMUNOTHERAPY: A NEW PARADIGM WITH UNANSWERED QUESTIONS

Zürich, Switzerland
3-4 July 2019

CO-CHAIRS: John B.A.G. Haanen, Netherlands
Aurélien Marabelle, France

SPEAKERS: Maurice Pérol, France
Solange Peters, Switzerland
David Planchard, France

LEARNING OBJECTIVES

- Understanding the key players in tumour immunology
- Getting up-to-date on the role of immunotherapy in advanced Non-Small-Cell Lung Cancer (NSCLC)
- Understanding the role of biomarkers in selecting NSCLC patients for IT
- Why should angiogenesis inhibition be combined with Check-Point Inhibitors
- How to manage IT toxicity and how to use IT in specific subgroups of patients

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 3 July 2019

09:00-09:10	Welcome and introduction John B.A.G. Haanen, NL
09:10-09:45	What every medical oncologist should know about Tumour Immunology
30'	John B.A.G. Haanen, NL
5'	Discussion
09:45-10:20	Session 1
30'	State-of-the-art: Immunotherapy with Immune Check-Point Inhibitors of Locally Advanced and Metastatic Non-Small-Cell Lung Cancer in first and later-lines Maurice Pérol, FR
5'	Discussion
10:20-10:50	<i>Coffee break</i>
10:50-11:15	Session 2
20'	Are all fit patients' candidates for first-line treatment with Immune Check-Point Inhibitors? Debate Pro: one size fits all! Maurice Pérol, FR
5'	Discussion
11:15-11:40	Debate Contra: Patients should be selected based on predictive biomarkers David Planchard, FR
20'	Discussion
5'	
11:40-12:05	Session 3
20'	In TPS>50%, what is best in first-line: single agent Pembrolizumab or CT-IO combination? Solange Peters, CH
5'	Discussion
12:05-12:20	Questions and Answers
12:20-13:20	<i>Lunch</i>
13:20-13:45	Session 4
20'	What is the rational for adding anti-angiogenics to Immune Check-Point Inhibitors? Solange Peters, CH
5'	Discussion
13:45-14:10	Session 5
20'	Refining patient selection: Immuno-score, -profiling, -gram and Tumour Mutation Burden The point of view of the Immunologist John B.A.G. Haanen, NL
5'	Discussion
14:10-14:35	Session 6
20'	Efficacy evaluation of Immune Check-Point Inhibitors: RECIST 1.1, iRECIST or irRECIST? The issue and risk of hyper-progression Brain metastasis as a target Aurélien Marabelle, FR
5'	Discussion
14:35-14:50	Questions and Answers
14:50-15:20	<i>Coffee break</i>

15:20-15:45	Session 7
20'	Toxicity issues with Immune Check-Point Inhibitors John B.A.G. Haanen, NL
5'	Discussion
15:45-16:10	Use of Check-Point Inhibitors in patients with AID and chronic viral infections
20'	Aurelién Marabelle, FR
5'	Discussion
16:10-16:30	Questions and Answers
<i>19:00</i>	<i>Networking dinner</i>

Thursday, 4 July 2019

09:00-12:30	Workshop sessions Three parallel workshop sessions with approx. 20 delegates in each group (delegates will attend all 3 sessions on a rotation basis) 15' Introduction based on clinical cases presented by speakers 35' Discussion 10' Break
Workshop 1	When to stop immunotherapy or treatment beyond progression Aurélien Marabelle, FR
Workshop 2	Choosing treatment based on biomarkers David Planchard, FR
Workshop 3	Managing toxicity John B.A.G. Haanen, NL
<i>11:00-11:30</i>	<i>Coffee break</i>
11:30-12:30	Workshops 1-2-3 continuation
12:30-13:15	Feedback on the workshops from each group
13:15-13:30	Synthesis and wrap-up John B.A.G. Haanen, NL Aurélien Marabelle, FR
<i>13:30-14:30</i>	<i>Lunch</i>